The global proton pump inhibitor market includes various drugs which are prescribed by healthcare professionals for treatments related to various gastrointestinal disorders such as duodenal ulcers, peptic ulcers, NSAIDS induced ulcers, and gasteroesophageal reflux disease. Proton pump inhibitors are a class of drugs that act on cell lining of stomach and reduce stomach acid in patients suffering from gastro-intestinal disorders. Proton pump inhibitors include drugs such as esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazol.
Market Dynamics
The global proton pump inhibitor market is expected to witness significant growth during the forecast period owing to focus of generic drug manufactures on obtaining approvals and launching products for treatment of gastro-intestinal diseases to strengthen their position in the global proton inhibitor market. For instance, in March 2020, Rosemont Pharmaceuticals, a pharmaceutical company, launched omeprazole powder for oral suspension, PPI approved for use on mg/kg basis and used in treatment of patients in age groups such as pediatric, adults. The omeprazole powder oral suspension is also licensed for use with percutaneous endoscopic gastonomy (PEG) and nasograstic (NG) tubes.
Key features of the study:
- This report provides in-depth analysis of the global proton pump inhibitor market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global proton pump inhibitor market based on the following parameters – company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study are AstraZeneca PLC/AB, Bayer AG, Pfizer Inc., Cadila Pharmaceuticals Limited, Eisai Pharmaceuticals India Pvt. Ltd, Santarus, Inc., Wyeth, LLC, Janssen Pharmaceutica, Takeda Pharmaceutical Company Limited, Sanofi S.A., Aurobindo Pharma, Perrigo Company plc, Dr. Reddy's Laboratories
- Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, market expansion, and marketing tactics
- The global proton pump inhibitor market report caters to various stakeholders in this industry including investors, suppliers, drugs manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global proton pump inhibitor
Detailed Segmentation:
- Global Proton Pump Inhibitor Market, By Type:
- Omeprazole
- Pantaprazole
- Rabeprazole
- Dexlansoprazole
- lansoprazole
- Others
- Global Proton Pump Inhibitor Market, By Disease Indication:
- Ulcers
- Gastroesophageal Reflux Disease
- Others
- Global Proton Pump Inhibitor Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Global Proton Pump Inhibitor Market, By Region:
- North America
- By Type:
- Omeprazole
- Pantaprazole
- Rabeprazole
- Dexlansoprazole
- lansoprazole
- Others
- By Disease Indication:
- Ulcers
- Gastroesophageal Reflux Disease
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Others
- By Country:
- Latin America
- By Type:
- Omeprazole
- Pantaprazole
- Rabeprazole
- Dexlansoprazole
- lansoprazole
- Others
- By Disease Indication:
- Ulcers
- Gastroesophageal Reflux Disease
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Others
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Type:
- Omeprazole
- Pantaprazole
- Rabeprazole
- Dexlansoprazole
- lansoprazole
- Others
- By Disease Indication:
- Ulcers
- Gastroesophageal Reflux Disease
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Others
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Type:
- Omeprazole
- Pantaprazole
- Rabeprazole
- Dexlansoprazole
- lansoprazole
- Others
- By Disease Indication:
- Ulcers
- Gastroesophageal Reflux Disease
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Others
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Type:
- Omeprazole
- Pantaprazole
- Rabeprazole
- Dexlansoprazole
- lansoprazole
- Others
- By Disease Indication:
- Ulcers
- Gastroesophageal Reflux Disease
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Others
- By Country/Region:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Type:
- Omeprazole
- Pantaprazole
- Rabeprazole
- Dexlansoprazole
- lansoprazole
- Others
- By Disease Indication:
- Ulcers
- Gastroesophageal Reflux Disease
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Others
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- AstraZeneca PLC/AB *
- Company Overview
- Material Portfolio
- Financial Performance
- Key Highlights
- Market Strategies
- Novo Nordisk A/S
- Bayer AG
- Pfizer Inc.
- Cadila Pharmaceuticals Limited
- Eisai Pharmaceuticals India Pvt. Ltd
- Santarus, Inc.
- Wyeth, LLC
- Janssen Pharmaceutica
- Takeda Pharmaceutical Company Limited
- Sanofi S.A.
- Aurobindo Pharma
- Perrigo Company plc
- Dr. Reddy's Laboratories
- Aralez Pharmaceuticals Inc.
- RedHill Biopharma Ltd (ADR)
- Cipla Limited
“*” marked represents similar segmentation in other categories in the respective section.
